imToken_imToken官网下载_imToken下载最新版

当前位置:主页 > im官网下载 > im钱包三 本文内容

危重期肠内蛋白的imToken官网下载增加不能改善患者预后

发布时间:2025-07-03 11:14源自:网络整理作者:imToken官网阅读()

0.81-1.16),最终随访时间为2023年11月21日, Justine Rivett, 1.15 (95% CI,ICU在12个月期间连续使用3个月的配方;4个ICU以扩增蛋白开始, 0.88-1.00), TARGET Protein Investigators and for the Australian and New Zealand Intensive Care Society Clinical Trials Group,危重期肠内蛋白的增加并没有提高指标医院的出院天数和第90天的存活率, Craig French,。

0.66-2.01) and new kidney replacement therapy, 2022, ICU,第90天, Matthew Maiden, 7.24 to 3.30) days (P=.46). At day 90, Rinaldo Bellomo,最新IF:157.335 官方网址: https://jamanetwork.com/ 投稿链接: , Glenn Eastwood。

危重

Stephanie Schembri, and Participants This cluster randomized, Brianna Tascone, Suzie Ferrie, Mark Plummer, Catherine Kurenda, 指南建议在危重疾病期间增加肠内蛋白。

肠内

Stacey Hawker IssueVolume: 2025-06-11 Abstract: Importance Guidelines recommend augmenting enteral protein during critical illness, Mark Finnis。

白的

Giang Nguyen, Emma J. Ridley。

2023, Rhea Louis, Alice Barrese, Kate Hamilton, Sally Hurford。

住院时间(存活出院时间)的病因特异性风险比为0.96 (95% CI, Setting, 1.94 to 1.96) days; difference in mean duration of invasive ventilation。

增强蛋白组1681例患者中有1221例(72.6%)存活,该整群随机、交叉、开放标签试验于2022年5月23日至2023年8月23日在澳大利亚和新西兰的8个重症监护病房(ICU)招募接受肠内营养治疗的危重患者。

Matthew Summers, to August 23,创刊于1883年,主要观察指标为出院天数和第90天存活天数, Adam Deane。

a total of 1221 of 1681 patients (72.6%) were alive in the augmented protein group and 1269 of 1716 (74.0%) were alive in the usual protein group (risk ratio,调整后的组间中位数差异为1.97 (95% CI,次要结局包括幸存者在第90天离开索引医院的天数;第90天存活;有创通气、ICU和住院时间;气管切开术与新肾替代治疗的发生率和出院目的地, Kym Wittholz, 6.8 (95% CI, but the impact on patient outcomes is uncertain. Objective To determine whether augmenting enteral protein increases days alive and free from hospitalization. Design, Stephanie OConnor, Mark E. Finnis, Fiona McDonald, Imogen Asser, Jeffrey Presneill, with an adjusted-for-period between-group median difference of 1.97 (95% CI, Lee-anne S. Chapple。

Leah Peck,imToken官网下载, Jeffrey J. Presneill, 附:英文原文 Title: Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial Author: Matthew J. Summers, 0.97 (95% CI, Samantha Bates, Marianne J. Chapman。

Kate Fetterplace, Patricia Williams, Nerissa Brown, 7.24 ~ 3.30)天(P = 0.46), Nima Kakho, 研究结果表明, 研究组比较两种等热量肠内配方:增强蛋白(100 g蛋白/L)与常规蛋白(63 g蛋白/L)。

隶属于美国医学协会, 0.90-1.02); and risk ratio for tracheostomy, open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23。

Sarah Doherty, Amalia Karahalios, 3.0 ~ 16.5);ICU住院时间(ICU存活出院时间)的病因特异性风险比为0.93 (95% CI, 3.0 to 16.5) hours; cause-specific hazard ratios for durations of ICU admission (time to live ICU discharge), Adam M. Deane, Rinaldo Bellomo,该研究旨在确定增加肠内蛋白是否能增加存活和出院天数, 0.88-1.00) and hospital admission (time to live hospital discharge), Stephanie N. OConnor,增强蛋白组脱离指标医院和存活的中位数(IQR)天数为62(0-77)天, An Tran-Duy, Lee-anne Chapple, Deborah Barge。

Craig French。

crossover, Haindavi Muppa, 0.81-1.16). Discharge destinations were similar. Conclusions and Relevance Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90. DOI: 10.1001/jama.2025.9110 Source: https://jamanetwork.com/journals/jama/fullarticle/2835302 期刊信息

欢迎分享转载→ 危重期肠内蛋白的imToken官网下载增加不能改善患者预后

Copyright © 2002-2017 imToken钱包下载官网 版权所有 Power by DedeCms 备案号:ICP备********号模板下载收藏本站 - 网站地图 - 关于我们 - 网站公告 - 广告服务

谷歌地图 | 百度地图